<SEC-DOCUMENT>0001144204-12-018943.txt : 20120620
<SEC-HEADER>0001144204-12-018943.hdr.sgml : 20120620
<ACCEPTANCE-DATETIME>20120330164546
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-12-018943
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20120330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: small-caps">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: small-caps">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: small-caps">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: small-caps"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; font-variant: small-caps">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="text-align: left; vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">March 30, 2012</TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt">Writer's Direct Number: (317) 236-2289</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Direct Fax: (317) 592-4666</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Internet: Stephen.Hackman@icemiller.com</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>BY EDGAR AND FEDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mr. Jeffrey Riedler, Assistant Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">U.S. Securities and Exchange Commission<BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Bioanalytical Systems, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Form 10-K filed
on December 29, 2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">File No. 000-23357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Mr. Riedler:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is
the response of the Company to the comments of the Staff contained in the Staff&rsquo;s letter to the Company, dated March 6, 2012,
relating to the Company's Form 10-K, filed on December 29, 2011 for the fiscal year ended September 30, 2011 (File no. 000-23357)
(the &quot;<U>Form 10-K</U>&quot;). For convenience of reference, the text of the comment in the Staff&rsquo;s letter has been
reproduced in bold type herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><U>Comment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 31.5pt">1.</TD><TD STYLE="text-align: justify"><B>We note that you entered into a Preferred Provider Agreement with Pharmasset, Inc., which has
become your largest client, and that in 2011 it accounted for 14.5% of your revenues. Please revise your disclosure to describe
the material terms of your agreement with Pharmasset including but not limited to any payment provisions, material obligations
that must be met by both parties to keep the agreement in place, duration and termination provisions. Also, please file the agreement
as an exhibit pursuant to Item 601(b)(10) of Regulation S-K. </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B><U>Response</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The disclosure
with respect to the Preferred Provider Agreement with Pharmasset has been revised to describe the material terms of the agreement
and will be filed with the Company's Amendment No. 1 to the Form 10-K. The following sets forth the revised disclosure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">With the
signing of the Preferred Provider Agreement (&ldquo;PPA&rdquo;) with Pharmasset, Inc. in the first quarter of the current fiscal
year, Pharmasset, Inc.&nbsp; has become our largest client, accounting for approximately 14.5% of our total revenues in fiscal
2011 and 6.3% of our total trade accounts receivable at September 30, 2011.&nbsp; Pfizer, Inc. remains a large client, accounting
for approximately 5.2% and 7.0% of our total revenues in fiscal 2011 and 2010, respectively. Pfizer, Inc. accounted for 4.2% and
4.7% of total trade accounts receivable at September 30, 2011 and 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Per the PPA
with Pharmasset, we will provide services for toxicology studies, pharmaceutical analyses and bioanalytical services as needed
by Pharmasset. We agree to assign a priority status to any Pharmasset study and to place the study in our schedule such that Pharmasset
will be able to meet its timelines and requirements.&nbsp; Pharmasset agrees to use the Company as its provider of first choice
for toxicology studies, but does not guarantee a specific level of projects.&nbsp; Pricing, per the PPA, is detailed in a pricing
list accompanying the agreement and is based on study specifics.&nbsp; A volume discount will also be applied to incremental services
provided and is based on annual billings.&nbsp; The PPA shall remain in effect for two years unless terminated earlier on mutual
written agreement of the parties, or on 90 days&rsquo; advance written notice by either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***********</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: maroon; border-bottom: Black 0.5pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: maroon">One American Square </FONT>|<FONT STYLE="color: maroon">
Suite 2900 </FONT>|<FONT STYLE="color: maroon"> Indianapolis, IN 46282-0200 </FONT>|<FONT STYLE="color: maroon"> P 317-236-2100
</FONT>|<FONT STYLE="color: maroon"> F 317-236-2219</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-top: Black 0.5pt solid"><FONT STYLE="color: maroon">INDIANAPOLIS
</FONT>|<FONT STYLE="color: maroon"> CHICAGO </FONT>|<FONT STYLE="color: maroon"> CLEVELAND </FONT>|<FONT STYLE="color: maroon">
COLUMBUS </FONT>|<FONT STYLE="color: maroon"> DUPAGE COUNTY IL </FONT>|<FONT STYLE="color: maroon"> WASHINGTON DC&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;www.icemiller.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-top: Black 0.5pt solid">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 30, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt">The Company acknowledges
that it is responsible for the adequacy and accuracy of all disclosures in the filing and that neither changes to its disclosure
in response to staff comments nor staff comments foreclose the Commission from taking any action with respect to the filing. The
Company hereby acknowledges that it may not assert staff comments as a defense in any proceeding initiated by the Commission or
any person under the federal securities laws of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#9;If you have any
questions regarding the Company's response in this letter, please call me at the direct-dial number above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR>
    <TD NOWRAP STYLE="width: 52%; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Very truly yours,</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">ICE MILLER LLP</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">/s/ Stephen J. Hackman</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Stephen J. Hackman</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``S`/,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BO#/AGX
MN\0:QXXMK2_U6XN;9XY&:-R,9`)!Z#_/Z>I>+_%UEX1TK[5<_O)Y"5A@4\N<
M9_(>M*YVU\#4HUE1W;['0T5\^IXC^(?CJ]D.DR7,4`/"VC>3''G.`7X)_$_E
MV=>2_$WP85O;JXO'MDR27E%Q%W^\.<#\OP[%SI_LJ2?+*I%2[7/H"BN0^'_C
M5O&6ERR36;V]S;D+(54^6^<X*G\.1VKS+Q;XH\6#X@W^D:3J=V,SB."WC8=2
M.@X]_P#/9W.>C@*E2K*DVDXZNY[Y17@YMOBZ3D-J7/\`TUC'7\??_..-'0;?
MXH_\)#I[:B]^+'[0AGWR1E=F[G(],'I_+'"N:RRU13?M8Z>9ZOK&DIJ]DT(N
M)[6=03#<V[E9(F(QD$=1ZCH:\8UKQOX_\&ZF^FZE<P3D9:.:2W!$J_W@0!Q[
M=J].\6>()]`O=-F3;)`Q?SH<X)7`YZ]?3MUSZB75M)T;Q]X>\J7#HP+0R@#S
M('Y&<=CQR#Z<T[&.#Q-.E+EK14H^FWH>4Z3\0?'OBK4$TS3);>.20?-)';C]
MVO=B3G`_S]/9="T9M)M/](O)[Z]DYFNIVRS'.<`=%49X`K,T#P_H_@'0'PR@
M@;KBY88:1O\`#T%0^&/$5QK^OWQ.8[6*(>7%Z9;J??@_3]`DBL;B:=27+1BH
MQ]-_7_(ZZBO.O%NKZI9^+HK>UU">*`K'F-2`!G=GMS^..G7`RO1>-[VYL?#K
M2VEP\$ID5=Z'!`.<_P"?Y=0S@.CHKG/!%[=W_AX37LSS2^=(-[]<9Z=!_GCC
MH.CH`**KW[M%IUS(K;66)V!]"`?<?SKBO`6KZCJ.IWL=Y>3SJL*L%DZ*=QZ<
M?7TZ=.R@'>T444`%%>5:WJ^OR>*;JRL+^Y`,Q2.*-AZ'I[_CV[8.USP>/">)
M-0&<YPZ\?>Z?G[=NG\+L!ZG17G6D0^,AK=FUZ][]D\X><&<;=OS>@]Q^G3^'
M4^(.HW^GV5D;&ZDM]\CAVC(!(V_3^H]>V0@.QHKRB/\`X3>ZA2>">_:*1<A@
MZ]"&Y'Y^W;I_"KZWXMT">*34'G:)F)VW`!5NO`8`?ED<<\?PNP'JU%4-'U:#
M6M-CO(`5#95D/5&'4?Y_2K](`HHHH`^0/C;_`,E>UW_MW_\`2>.BCXV_\E>U
MW_MW_P#2>.B@#LOA#_R4.TQT\F7I_NGZ?Y_2S\5;B;5_B0NG;V"1+%;Q@\A2
MW)([=6_3VXK?"'_DH=ICIY,O3_=/T_S^FK\8]%N-,\56^O6ZN(KI5S)UVS(.
M!GK]T`CZ''3A/8^MFXK,E??ET]3VO2=*L]$TR'3["$16\(PH`ZGN3[D\U;EC
M2:)XI%#QNI5E/0@]17->#_&FG>*]+ADAE5+T#;/;,P#(V.2!W4XX(_3!QK:U
MKNF^'["2\U*Z2&-%R%)&Y_91U)IGS$Z5557"2?-?\2MJ=U9>#O"UQ=6UDJVE
MDFX6\.%&,]OSKYWN/%,4_P`0U\3K:NL0NTN?(W?-A<9&<>U?0.B>(="\<Z1*
M+<QW$1&VXM9UY7/]Y3U!QP?;U%>):CIUBGQF&GK:V\=B=0C0P>6!&%.,C;TQ
MUX_EV1[.5\L)5(U8OFL[^FAV?_"]K'_H!77_`'^7_"O1/#.NQ^)?#UKJ\4#0
M)<;L1LP8C#%>H^E5#X0\($DG1-)YR>($'KGM]?R]JV+*"PL;=+2QCMX(1DI%
M"`JC)).`/?-.QYN(J8:4;48-/U.*^)A^731E#AG.,X*\#GK_`)Y.1U&)I]SJ
M7@^2RN]IDL+Q!(Z@X4\'CV8>^/R'R;?Q,/RZ:,H<,YQG!7@<]?\`/)R.HZ+2
M=/M]0\'6-I=0JT3VZY4'H<<$'L>_;![#I3Z'"<+J%[J?C2_F^SH8[*T0R$,=
MJQ@!L$^K$KC';V()6]\-!_Q-+_CI"O&,8^8]./;GZ#IT7LUTRTT;P[<6EE&(
MHDAD;KR20223D<_E^`%<9\-!_P`32_XZ0KQC&/F/3CVY^@Z=%`*_C4D>-X,'
MC;%D$XQR3G]/;IGME>H^(!QX8/./WR=_K[C_`#Z=1R_C4D>-X,'C;%D$XQR3
MG]/;IGME>H^(!QX8/./WR=_K[C_/IU`,;\/%V^%P-H7]_)P/P]A_GCCH.KKD
MOA\\<7AC#%(SY\AQG'X]!Z'\CTQ@:'BK69M(T5KFS>(S"0+\PW8!SGC(]#^1
MZ=0@-/4CC2[LYQB%^<X_A/N/YBO/OAJ,:M?#GB`<;>!\WT]O;ITXPO3:+JMS
MJ_A"ZO+LJ)MLRG:-H``./3^8YST[<Q\-RL>J7S,P51`!AL`#D]./]DYZ=.G9
M6@/3*I:OJ2Z1I<]\\+RI"NYE3&<>O-27=TL%G/*CQ[XXV8`D=0#[CT/<=#7)
M^%?$%UXFN+RSU*&!X5B5M@C(&=V._P!/;!'U"H#C#K,1\6+K+6Y\L3^<8RP)
M'!Z$CV[],?[/R=;_`,++@XSID@YY_>C@?B/8]<?HV.?>UMQ\0?LHAC6U%WM,
M8^50OH`.W'3V]OD]&_L30D)(L+)2`1PBC'7/\C_WS[##`GTC41JVE07RQ-$)
M0?D8\C!(_I7'?$BX@EM[!(Y8G>.5]P#@LF!C\.1ZCH>F,CN+:.UM8EMK98HH
MU)"QI@`<G@#\#^1KR_QEX=.D71OQ<*ZW=P[!`A7RQ][KGG''ITSP`-@@.V\+
MWMI!X8L(Y;J&-EBY5Y`".3V[=#Z=.@Z"CXVUC2VT*:T^TQ2W#D;$C<,4(.<G
M!XZ'_()'/:5\/_[3TNWODOTB,BEPA@^ZV2.H(_D"/0<;<?2[2ST[Q&MIK<12
M&.1ED"G"J>S'`Y7C.1CU_APH!W7P\M);?P_([AE268LB$8&,`$CZG/IT[=!U
MU8_B*\FTG0'FL=D;HR(@V94#<!C'IC_(ZC1O96@L+B5"`R1,P)QP0">](">B
MLSP]>3W^@6=U=.'GD3+D+@$Y(Z=O\\#I6+-JFHW&M:E;VVL65I#:LH`GC4]5
M)/.><;3G_@73L`?-OQM_Y*]KO_;O_P"D\=%9OQ/U&35OB)JE]+&B22B'*H<K
MQ"@R/8XS10![_P""?A;J/A;Q/!JL^HVLT<:.K)&K`G<I']:]&U72K'6].EL-
M1MTGMI1AD;^8/8^XINC7[:IHUI?.BHT\8<JIR!GM5/1M5N=2O+Y9?*$4$TD2
M*L3AAM=ER6/RG..W3]`CHKXJK6J*I-ZH\OU?X(WD-SYV@ZJA7<2J7&49.N/G
M7.?R'^%>S^"VO7DZG5]7MXXQG)5FF;T&,@?S]/P]0M-?N;G6XX&2W2UEGG@1
M?G,F8BREMV-N"4;C.0!WY"R+XDB;Q>=$!B*^5PV_Y_-`W%<>FW!SZY'K@T.M
M9MBDK7^=M23PWX6TOPKIXM--A(SS)*_+R'U)_H.*\]\4_"+4M>\37^J0:E:1
M1W+[PCJQ(X`KT^&]>36;NR**$@ABD5N<DN9`?_0!4UY<K96-Q=.,I#&TC#..
M`,_TH:T.:CC:U*HZD7[S[ZGB7_"B]7_Z"]C_`-\-_A6CH/P<U71_$&GZD^J6
M;K;7"2LJHV2`<\<5Z?H]UJ-S:"YU%+6..2))8S"S<!@25;/IQSW]!5+1->O-
M0NX$N;>%(KNU-W`8G)*+NQAL]3ADZ=R1BE9'3+-L5).+?X$?BSPW<^(39B":
M&-8"Q)D!R"<<C'T]OKW&SI5F=/TFULV*EH8E0E1P2!V_S^`K/L]<FN+NS@>&
M-?/FNXV*MG;Y,A08]<XSZ^W7%6V\43S:Z^F26B1G[:T,;[R?-B".2PXZAEP1
MR,$'OP[GF6.@NHFGLYX4(5I(V4$YX)&.W-<SX2\*7/A^ZN)KB>&3S4"*L8/R
MX.<]!UX_(=L`:DVJ7,/B2*QF6&"TE`$4CJQ,[[7)56'RJPV@X.21G'LR]UBX
M@\3V>EQHGE2Q>:[F-W/WL8!7A?7)_P#KAW"QE:_X1O-6\01ZC#=0I&H0;'SD
M;3G(Q^'Y>N"-CQ+I$VMZ3]CAE2)C(K%GSC`^G^?H<$6KB^>'5[&S6,,EPDK,
M_P#=V[<?GN_SVO4`>:I\-]27&+ZV7D@XW<#\`/Z=/IM!\-]2^7-];#!Q_%P/
M;@?TZ=N-OI5%`&#H>A3Z5X;ETQY8VD;S-K)G:-W3T/\`GC%<FGPWU)=N+ZU4
M\@[=W`_`#\N.GTV^E44`>:K\.=3&W_3[9<9'&[A?;@?EQT^FW>\)^%+GP_=W
M$\]Q%()(]BI&/N\YST'M^7I@#K**`."U;P)?ZAK%S>QWD"+-(6P=V0#_`)]>
MW7IMI+\.=3&W_3[9<9'&[A?;@?EQT^FWTJB@#@=(\!WVGZM9W<MW;ND$FXJN
M<X'3'&/3\OIMW/%GAV;Q##:)!+%$T,A8M(#T(QQCG/XC\\$=%10!0T6PDTS1
MK6RE96>%-I*].O\`G_ZU9'BGPF->>&>WE2"Y3Y69@<,OX=Q_GD`CIJ*`.830
M-5E\+OI%U>P&0,OE2@,WR@YPW3/3'\L<8?\`V3KUQ>+->:C;F-89(_+A#*"6
M7`SZX/TZ9],=)10!R4'A_P`0165I8KJ=M%;6[H1Y:L&(!S@GN.>G`XXQD;;4
M'@[3EU:^N[BVMIHYW62)"G^J;G<?Q.#^'I@#HZ*`/C[XU(L?Q;UM$4*BBW"J
MHP`/L\?`HIWQM_Y*]KO_`&[_`/I/'10!2T[XL>.-)B,5GK\RQ'HCPQR*HYX4
M,I"CGH,=O04MG\6O'5A+/);Z_(IG=I'4P1,NXDDD*5(7))Z`4446`BB^*'C.
M'43?QZVXGWM)_J(M@=@0S!-NT$@G)`S4@^*_C42"3^V1O%P;D,;2`GS",%L[
M/3C'3&!V%%%`"GXM>.O[4_M$:_(MR4$;%8(E5E&[&Y`NUL;FY(_D*MGXU_$)
ME*MX@!!&"#96_/\`Y#HHH`I:=\5O&^E*ZV>NN@<`$/!%)@#.`-RG`&>`.!3;
M#XI>,],F>6TUDH[@KS;0L$4L6VH"A"+D_=7`Z<<"BB@`M_BEXSM=0>^AUMUG
M8L<F"(J"QRQ52NU<GDX`S@>E(?BCXQ-W#='5E,\$[W$;FTARLCKM8_<[CMTX
M!Z@4446`EF^+/CFXOHKR;7Y7EB(**T$7E@C.#LV[<\GG&?R%$WQ:\<SZA%?O
MK\HN8EVJR0Q("N<X("@,,]B#1118`O/BSXYOYH)I]?E$MN3Y;Q0Q1D9QD951
MD'`X/'`JY_PNWXA_]##_`.25O_\`&Z**`#_A=OQ#_P"AA_\`)*W_`/C='_"[
M?B'_`-##_P"25O\`_&Z**`#_`(7;\0_^AA_\DK?_`.-T?\+M^(?_`$,/_DE;
M_P#QNBB@`_X7;\0_^AA_\DK?_P"-T?\`"[?B'_T,/_DE;_\`QNBB@`_X7;\0
M_P#H8?\`R2M__C='_"[?B'_T,/\`Y)6__P`;HHH`/^%V_$/_`*&'_P`DK?\`
M^-T?\+M^(?\`T,/_`))6_P#\;HHH`/\`A=OQ#_Z&'_R2M_\`XW1_PNWXA_\`
M0P_^25O_`/&Z**`#_A=OQ#_Z&'_R2M__`(W1_P`+M^(?_0P_^25O_P#&Z**`
M#_A=OQ#_`.AA_P#)*W_^-T?\+M^(?_0P_P#DE;__`!NBB@#C];UO4?$>L3ZM
:JUQ]HOI]OF2[%3=M4*.%``X`'`HHHH`__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
